Compare AZN & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZN | TMO |
|---|---|---|
| Founded | 1992 | 1956 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.7B | 255.1B |
| IPO Year | 1995 | 1996 |
| Metric | AZN | TMO |
|---|---|---|
| Price | $171.44 | $671.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 28 |
| Target Price | $207.16 | ★ $690.62 |
| AVG Volume (30 Days) | ★ 2.4M | 2.2M |
| Earning Date | 10-30-2026 | 10-21-2026 |
| Dividend Yield | ★ 1.87% | 0.28% |
| EPS Growth | N/A | ★ 7.32 |
| EPS | N/A | ★ 9.10 |
| Revenue | N/A | ★ $20,918,000,000.00 |
| Revenue This Year | $7.94 | $7.47 |
| Revenue Next Year | $6.26 | $5.17 |
| P/E Ratio | ★ $31.91 | $74.26 |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $80.48 | $435.27 |
| 52 Week High | $212.71 | $705.79 |
| Indicator | AZN | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 62.32 | 53.19 |
| Support Level | $154.70 | $635.32 |
| Resistance Level | $175.04 | $694.33 |
| Average True Range (ATR) | 3.14 | 22.47 |
| MACD | 1.44 | -1.29 |
| Stochastic Oscillator | 87.44 | 52.45 |
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).